GH Research PLC Total Liabilities
GH Research PLC total liabilities. Based on the latest financial reports, GH Research PLC (GHRS) has total liabilities worth $12.86 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GHRS financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of GH Research PLC (2019–2025)
Total liabilities of GH Research PLC from 2019 to 2025. This chart illustrates how GH Research PLC's total liabilities have evolved over time, based on quarterly financial data. Explore GHRS long-term investments to assets to see how much of total assets are deployed in long-term investments.
GH Research PLC Competitors by Total Liabilities
The table below lists competitors of GH Research PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BlackRock ESG Capital Allocation Trust
NYSE:ECAT
|
USA | $182.33 Million |
|
East Group Co Ltd
SHE:300376
|
China | CN¥6.43 Billion |
|
Suzhou Veichi Electric Co. Ltd. A
SHG:688698
|
China | CN¥1.29 Billion |
|
Guizhou Redstar Developing Co Ltd
SHG:600367
|
China | CN¥635.88 Million |
|
Olaplex Holdings Inc
NASDAQ:OLPX
|
USA | $582.21 Million |
|
SonoScape Medical Corp
SHE:300633
|
China | CN¥1.04 Billion |
|
WeRide Inc. American Depositary Shares
NASDAQ:WRD
|
USA | $1.36 Billion |
|
Hunan TV & Broadcast Intermediary Co Ltd
SHE:000917
|
China | CN¥5.55 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down GH Research PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GHRS current and non-current assets.
Liquidity & Leverage Metrics
GH Research PLC Total Liabilities Ratios Explained
GH Research PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GH Research PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GH Research PLC (2019–2025)
The table below shows the annual total liabilities of GH Research PLC from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.53 Million | -8.53% |
| 2024-12-31 | $9.32 Million | +27.14% |
| 2023-12-31 | $7.33 Million | +61.28% |
| 2022-12-31 | $4.55 Million | +65.37% |
| 2021-12-31 | $2.75 Million | +1017.48% |
| 2020-12-31 | $246.00K | +136.54% |
| 2019-12-31 | $104.00K | -- |
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more